We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





HORIBA Exhibits Compact Benchtop Hematology Analyzers

By LabMedica International staff writers
Posted on 03 Feb 2025

HORIBA (Kyoto, Japan) is presenting its latest IVD solutions at Medlab Middle East 2025, including the

labmedica.com/expo/product/4456/automated-hematology-analyzer-model-yumizen-h550" target="_blank">Yumizen H550 and H500 hematology analyzers.

The HORIBA Medical Segment designs, develops, and distributes worldwide, in vitro diagnostic systems mainly destined for biological analysis in medical laboratories. These automated analyzers meet the needs of various users including patients, doctors, private laboratories, clinics, and university hospitals. HORIBA’s expertise in vitro diagnostics is one of the most respected in hematology worldwide. The new generation of HORIBA’s automated hematology analyzer offers solid and reliable diagnostic technology as well as rapid and consistent results. HORIBA provides a wide range of hematology analyzers and automated instruments to realize blood analysis (blood cell identification and counting) for the diagnosis of various blood-related diseases. These instruments are designed for all kinds of laboratories, from small laboratories (to 150 patients a day), to larger ones (more than 2000 patients a day). These efficient and reliable instruments feature automated racks, data management, and quality tools providing a complete solution for meeting high-quality medical analysis requirements.

The new Yumizen H500 and H550 compact benchtop hematology analyzers featured at Medlab Middle East 2025 deliver enhanced performance, new features, and increased benefits. Both analyzers come with optional infectious flags for malaria and dengue, making them ideal for small labs to meet a variety of clinical lab environments and settings such as routine hematology, satellite labs, oncology care, and blood banks. HORIBA is also highlighting HELO 2.0, an innovative solution covering all the needs of a high throughput automated hematology platform. Flexible and efficient, HELO 2.0 is the optimum answer to the constant evolution of laboratories. Thanks to its data, tube management, waste, blood film, and digitalization management capability, HELO 2.0 not only fulfills all the needs of laboratories but also helps optimize their TAT, floor space, and reagent storage.


New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Clinical Informatics Platform
CLARION™
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.